explore -WSS

explore

author：leisure time 2025-09-28 23:47:11 - browse：24

Home health and hospice chain Amedisys has chosen a new corporate owner.

Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

hotspot

WSS

The woman behind the Dana Farber

Cigna, Humana reportedly in talks to merge

STAT letters to the editor on burnt

With clinical trial data readouts, here's how to spot spin

AI models in health care face new federal disclosure requirements

Diagnostic tests are hitting their mathematical limits

hotspot

explore

hotspot

Walensky prepares to leave CDC — and Congress — behind

Why sickle cell disease is getting the first CRISPR treatment

Moonlake's readout produced a cash windfall. Risks remain

30 years of 'Listening to Prozac'

Trump demands the U.S. pay no more for drugs than other countries … again

BIO selects John Crowley as new CEO

In Memoriam: Notable people who died in 2023

UnitedHealth’s Optum accused of antitrust violations in California

New air purifier tech could be key to improving indoor air quality

Spinal cord stimulation reduces pain in amputees, study finds

hotspot

STAT letters to the editor on burnt

UnitedHealth’s Optum accused of antitrust violations in California

FDA approves world's first CRISPR

BIO selects John Crowley as new CEO

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

hotspot

knowledge

focus

explore